Navigation Links
Butamax™ Responds to Gevo Patent Infringement Lawsuit
Date:4/10/2012

WILMINGTON, Del., April 10, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the biobutanol technology leader, commented on the lawsuit filed by Gevo today alleging patent infringement.

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

"Certain innovative technology is critical for commercial production of isobutanol.  This is especially true for the fundamental biosynthetic pathway claimed in our '188, '889 and related patents filed by Butamax several years ago," said Paul Beckwith, Butamax CEO.  "However, it is our view that the obvious modifications claimed in this recent Gevo patent, reliant on the fundamental pathway, are in fact not critical for our commercialization strategy."

The Butamax patents which are the subject of a lawsuit filed by Butamax against Gevo cover microorganisms which have been engineered to express the required enzymes for isobutanol production, methods of using these microorganisms as well as techniques for recovering isobutanol.  Accordingly, these patents cover fundamental steps for commercial production.  The trial date for the Butamax lawsuit is scheduled for April 2013. 

About Butamax

Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.  

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:
Pam Schools 910-777-7119
pamela.schools@butamax.com


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Icahn Responds to Cornelius
2. NeurogesX Responds to EMEAs Day 120 Questions
3. HealthCore Responds to Need for Real-world Health Outcomes Information on Drugs and Devices with Physician Network and Prospective Effectiveness Research
4. Amylin Responds to Eastbourne Letter
5. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
6. Immucor Responds To FDA Notice
7. Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases
8. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
9. Datafarm Responds to Health Canada's Announcement of Hybrid eCTD Submission Procedural Simplification
10. China Biologic Products Responds to Allegations on Financial Websites
11. Burrill & Company Responds to Recent Press Coverage About Biopark Investment at Elk Run
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Dovetail Genomics™ LLC today announced that it has ... planned metagenomic genome assembly service. Richard Green , ... method in a talk on Friday, February 12 at ... in Orlando, Fla. ... difficult. Using its proprietary Chicago ™ ...
(Date:2/11/2016)... --  BioInformant announces the February 2016 release of ... Tools, and Technologies – Market Size, Segments, Trends, and ... The first and only market research ... has more than a decade of historical information on ... cell type. This powerful 175 page global strategic report ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to ... in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of 2014. ... to SEK 517.6 M (loss: 30.0). Earnings per share increased ... was SEK 537.4 M (neg: 74.7). , ... Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/3/2016)... -- Vigilant Solutions announces today that the ... solved two recent hit-and-run cases with the ... Solutions. Brian Wenberg explains, "I was ... out of a convenience store and witnessed an elderly male back out ... his vehicle and leaving the scene.  In his statement ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
Breaking Biology News(10 mins):